Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients with Molecularly Selected Cancers (ATTACC)
Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer
Sponsor: Repare Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAT7370
U.S. Govt. ID: NCT04972110
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The study is being done to learn how safe and effective the study drug, RP-3500, is when given with either niraparib or olaparib to treat advanced cancer. Niraparib and olaparib belong to a group of drugs called PARP inhibitors. These drugs are designed to block an enzyme called PARP which may stop cancer cells from growing. RP 3500 belongs to a class of drugs called ATR inhibitors that are designed to stop cancer cells from growing. Cancers include: bladder cancer, brain and spinal tumors, breast cancer, colon and rectal cancer, esophageal cancer, head and neck/oral cancers, liver cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, and stomach cancer.
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced or metastatic cancer? Yes No
Have you ever received therapy with another ATRi or DNA-PK inhibitor? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator